Hypoparathyroidism

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
4 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
A Gastroenterology (ATC A) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Phase III: 4 Phase II: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

4 trials
  • Alexion Pharmaceuticals Inc. Commercial
    [ALA1,3,12,GLN10,ARG11,TRP14]PTH(1-14)/[ALA18,22, LYS26]PTHRP(15-36)COOH; ALFACALCIDOL; CALCITRIOL; CALCIUM CARBONATE
    2022-503126-12-01 10 countries 2024 n=112 Orphan
    Recruiting
  • Amolyt Pharma Commercial
    [ALA1,3,12,GLN10,ARG11,TRP14]PTH(1-14)/[ALA18,22, LYS26]PTHRP(15-36)COOH; ALFACALCIDOL; CALCITRIOL; CALCIUM CARBONATE
    2022-503126-12-00 1 country n=12 Orphan
    Not authorised
  • Ascendis Pharma Bone Diseases A/S Commercial
    PALOPEGTERIPARATIDE
    2025-523928-52-00 4 countries 2026 n=11 Orphan
    Recruiting
  • Bellvitge University Hospital Academic
    IMP not specified
    2023-509130-18-00 1 country n=394
    Pending

Phase II

1 trial
  • Ascendis Pharma Bone Diseases A/S Commercial
    PALOPEGTERIPARATIDE
    2024-512967-29-00 4 countries 2019 n=21 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ascendis Pharma Bone Diseases A/S Commercial 2 Phase II, Phase III 1
Alexion Pharmaceuticals Inc. Commercial 1 Phase III 1
Amolyt Pharma Commercial 1 Phase III 0
Bellvitge University Hospital Academic 1 Phase III 0
New trials by year
2019
1
2024
1
2026
1
← All indication landscapes